Anti-BACE 1, C-Terminus (485-501) antibody produced in rabbit

enhanced validation

affinity isolated antibody, buffered aqueous solution

Anti-β-Site APP Cleaving Enzyme
MDL number:
Pricing and availability is not currently available.

biological source


antibody form

affinity isolated antibody

antibody product type

primary antibodies




buffered aqueous solution

mol wt

antigen 70 kDa

species reactivity


enhanced validation

recombinant expression
Learn more about Antibody Enhanced Validation


microarray: suitable
western blot: 1:1,000 using a whole cell extract from the human kidney HEK293 cell line stably transfected with human BACE-1



UniProt accession no.

shipped in

dry ice

storage temp.


Gene Information

human ... BACE1(23621)

General description

BACE-1 (β-site APP cleaving enzyme, Asp2 or memapsin 2) is known as β-secretase. BACE-1 is highly expressed in neurons, the major site of Aβ generation. BACE-1 is localized within the Golgi and endosomal compartments, among the several intracellular sites where Aβ is thought to be produced. It constitutes the predominant β-secretase activity in human brain tissue.


synthetic peptide corresponding to the C-terminus of human BACE-1 (amino acids 485-501).


Anti-BACE 1, C-Terminus (485-501) antibody produced in rabbit has been used in western blotting.

Biochem/physiol Actions

Overexpression of β-site APP cleaving enzyme (BACE-1) leads to increased β-secretase activity while displaying appropriate cleavage site specificity for amyloid precursor protein (APP).

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 1% bovine serum albumin and 15 mM sodium azide.


Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
S Prasad Gabbita et al.
PloS one, 10(10), e0137305-e0137305 (2015-10-06)
Cytokines such as TNFα can polarize microglia/macrophages into different neuroinflammatory types. Skewing of the phenotype towards a cytotoxic state is thought to impair phagocytosis and has been described in Alzheimer's Disease (AD). Neuroinflammation can be perpetuated by a cycle of...
Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms
Grimm MOW, et al.
Test, 286(16), 14028-14039 (2011)
Marcus O W Grimm et al.
International journal of molecular sciences, 17(11) (2016-11-02)
One of the characteristics of Alzheimer´s disease (AD) is an increased amyloid load and an enhanced level of reactive oxidative species (ROS). Vitamin E has known beneficial neuroprotective effects, and previously, some studies suggested that vitamin E is associated with...
beta-Site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways
Tamagno E, et al.
Journal of Neurochemistry, 92(3), 628-636 (2005)
Marcus O W Grimm et al.
The Journal of biological chemistry, 283(17), 11302-11311 (2008-03-01)
The major molecular risk factor for Alzheimer disease so far identified is the amyloidogenic peptide Abeta(42). In addition, growing evidence suggests a role of cholesterol in Alzheimer disease pathology and Abeta generation. However, the cellular mechanism of lipid-dependent Abeta production...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.